Presentation: Specific sublingual immunotherapy in Korean patients with atopic dermatitis ( World Allergy Congress)

Wednesday, 14 October 2015

Hall D1 Foyer (Floor 3) (Coex Convention Center)

Byung Soo Kim, MD, PhD , Department of Dermatology, Pusan National University, Pusan, South Korea

Hyun-Joo Lee, MD , Department of Dermatology, Pusan National University, Pusan, South Korea

Jeong-Min Kim, MD , Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, South Korea

Gun-Wook Kim, MD , Department of Dermatology, Pusan National University, Pusan, South Korea

Je-Ho Mun, MD , Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, South Korea

Hoon-Soo Kim, MD , Department of Dermatology, Pusan National University, Pusan, South Korea

Margaret Song, MD , Department of Dermatology, Pusan National University, Pusan, South Korea

Hyun-Chang Ko, MD , Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, South Korea

Moon-Bum Kim, MD, PhD , Department of Dermatology, Pusan National University, Pusan, South Korea

Background: Sublingual immunotherapy (SLIT) with house dust mites (HDM) preparation has recently been proven to be beneficial for treating allergic rhinitis and asthma. However, there has been no report regarding the efficacy and safety of SLIT in Korean patients with atopic dermatitis (AD).

Objective: To investigate the efficacy and safety of SLIT in Korean patients with AD

Methods: A total of 34 patients with AD and IgE-proven HDM sensitization (Class ≥ 3) were recruited from Pusan National University Hospital between July 2011 and September 2014. Patients were treated with SLIT for at least 12 months. Eczema area and severity index (EASI) score, total serum IgE level, results of specific IgE assays to Dermatophagoides pteronyssinus and D. farinae, and adverse effects were recorded at each scheduled visit. “Responder” was defined as a patient with ≥ 30% improvement in EASI score after SLIT.

Results: Twenty-three patients continued SLIT for 12 months or more, and 11 patients (32.4%) dropped out because of exacerbation of dermatitis or were lost to follow-up. The average duration of SLIT treatment was 22.4 months (range, 12–32 months). EASI scores reduced significantly after 12 months of treatment (p < 0.001) compared with those at baseline. A total of 19 patients (19/23; 82.6%) were determined to be responders to SLIT after 12 months. Total and specific IgE serum levels did not significantly reduce after SLIT. No patients experienced serious adverse events, with the exception of two patients who developed transient lip and tongue swelling.

Conclusion: Our study demonstrated that SLIT with HDM extracts is effective and tolerable in Korean patients with AD. Further controlled long-term trials are required to reinforce the current results.

1077 Specific sublingual immunotherapy in Korean patients with atopic dermatitis